Down-regulation of GPRC5A Confers Protection Against Periodontitis Authors: Yuhan Hu, Runxuan Liu, Xinxiao Chen, Lingling Shang Published: 2026 ABSTRACT Periodontitis, a common chronic inflammatory disease, causes connective tissue degradation, alveolar bone resorption, and tooth loss. G protein coupled receptor class C group 5 member A (GPRC5A) regulates chronic inflammation in several diseases, but its role in periodontitis remains unclear. This study investigated GPRC5A expression and function in periodontitis. In human tissues, GPRC5A expression was assessed by immunohistochemistry and quantitative real-time PCR (qRT-PCR). In vivo, adeno associated virus (AAV) mediated GPRC5A silencing was applied in a murine periodontitis model. In vitro, mechanistic studies used small interfering RNA (siRNA) knockdown, co-immunoprecipitation (Co-IP), mass spectrometry, and western blot in periodontal ligament cells (PDLCs). GPRC5A was upregulated in inflamed periodontal tissues, and its downregulation reduced alveolar bone loss and periodontitis severity in mice. GPRC5A knockdown suppressed inflammatory cytokine production and NF-κB activation in lipopolysaccharide (LPS) stimulated PDLCs. β-arrestin 2 (ARRB2) expression paralleled GPRC5A changes, and mass spectrometry/Co-IP identified eukaryotic elongation factor 2 (EEF2) as an ARRB2 binding partner. GPRC5A silencing reduced LPS induced ARRB2 expression and EEF2 phosphorylation. These data suggest a possible mechanistic link that GPRC5A downregulation mitigates periodontitis through the ARRB2‑EEF2 pathway, though direct evidence of causality is still needed.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10753-026-02539-x. Introduction Chronic periodontitis, a highly prevalent oral infectious disease, is characterized by progressive destruction of periodontal connective tissues and alveolar bone resorption, which may ultimately result in tooth mobility and loss [1]. Periodontal pathogens trigger host immune responses by releasing various toxic metabolites, including endotoxins, which induce excessive secretion of inflammatory cytokines [2, 3]. This cascade disrupts periodontal immune homeostasis, leading to secondary damage of periodontal supporting tissues [2]. Periodontal ligament is a dense connective tissue that attaches the tooth root to the inner wall of the alveolar bone and is functionally important for tooth support [3]. Periodontal ligament cells (PDLCs), as essential constituents of the periodontal ligament, play indispensable roles in maintaining periodontal homeostasis [4]. Under sustained stimulation by bacterial products such as lipopolysaccharide (LPS), PDLCs overexpress pro-inflammatory cytokines such as interleukin (IL)-6 and IL-1β, thereby exacerbating periodontal inflammation and contributing to progressive destruction of periodontal supportive tissues [5, 6]. IL-8 is a key chemokine for neutrophil recruitment and is highly expressed in periodontitis lesions, promoting inflammatory infiltration. Prostaglandin-endoperoxide synthase 2 (PTGS2) and its product prostaglandin E2 (PGE2) are critical mediators of alveolar bone resorption. Therefore, these markers are widely used to assess the severity of periodontal inflammatory responses [1, 5, 6]. The current treatment of periodontitis mainly depends on periodontal debridement, which can alleviate the symptoms to a certain extent, but does not fundamentally inhibit the persistent progression of inflammation [7]. Therefore, elucidating key molecular regulators of periodontal inflammatory responses and their mechanisms may reveal novel therapeutic targets and strategies for better control of disease progression. G-protein-coupled receptors (GPCRs), the largest family of cell-surface molecules involved in signal transmission, play critical roles in physiological and pathological processes [8]. Studies have shown that most GPCRs serve as critical regulators in inflammation [9–11]. By participating in inflammation through coupling with G proteins and arrestins, GPCRs have become key therapeutic targets for various drugs and are widely used in the treatment of inflammatory diseases [12]. G protein-coupled receptor class C group 5 member A (GPRC5A) belongs to the GPCRs superfamily and participates in diverse pathological processes, including inflammation, immune responses, tissue injury, and tumorigenesis [13, 14]. GPRC5A is highly expressed in normal lung tissues, where it contributes to pulmonary homeostasis [15]. Studies demonstrated that GPRC5A deficiency led to aberrant activation of the nuclear factor-kappa B (NF-κB) signaling pathway in murine bronchoalveolar epithelial cells, increasing susceptibility to LPS-induced pulmonary edema, tissue damage, and inflammatory progression [15–17]. In contrast, elevated GPRC5A expression in inflammatory bowel disease exacerbated colonic oxidative stress by dysregulating glutathione metabolism via NF-κB signaling, impairing reactive oxygen species (ROS) scavenging capacity, and amplifying inflammatory responses [18]. These observations indicate regulatory roles of GPRC5A in inflammation [15]. Although periodontitis is a common chronic oral inflammatory disease with systemic implications [19], the inflammatory regulatory role and underlying mechanisms of GPRC5A in periodontitis remain unexplored. A preliminary study by our group reported that GPRC5A knockdown inhibited LPS‑induced inflammatory responses in human gingival fibroblasts [20]. Extending these findings, the present study combined human tissue analysis, Gprc5a knockdown in a murine periodontitis model, and in vitro PDLCs intervention to further elucidate the regulatory role and molecular mechanism of GPRC5A in periodontitis, aiming to provide a novel potential therapeutic target for periodontitis. Materials and Methods Detailed protocols for RNA isolation, quantitative real-time PCR (qRT-PCR), and western blot are described in the Supplementary Information Materials and Methods. Mice All the experimental procedures were approved by the Medical Ethical Committee of Stomatological Hospital, Shandong University (Permit Number: 20231208) and performed according to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. A total of 32 specific pathogen-free C57BL/6 mice (male, 6–8 weeks, 20–25 g, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd, China) were housed in the Laboratory Animal Center of Shandong University. Before starting the formal experiments, all mice were acclimatized to the environment for a week. Administration of Adeno-Associated Virus (AAV) AAV targeting Gprc5a for knockdown (AAV-shRNA-Gprc5a) was designed and manufactured by Vigene Biosciences (Shandong, China). The sequence of AAV-shRNA-Gprc5a was 5′-GTCCGTACAATGACTACGA-3′. Mice were randomly assigned to four groups (n = 8 per group) using a computer-generated random number sequence: wild-type mice with AAV-NC treatment (AAV-NC-Control), wild-type mice with AAV-shRNA-Gprc5a treatment (AAV-shRNA-Gprc5a-Control), periodontitis with AAV-NC treatment (AAV-NC-Periodontitis), and periodontitis with AAV-shRNA-Gprc5a treatment (AAV-shRNA-Gprc5a-Periodontitis). The investigator performing ligature placement, AAV injections, sample collection, micro-CT scanning, and histological assessments was blinded to group allocation. Blinding was maintained until all data were analysed. AAV-NC is a negative control AAV corresponding to AAV-shRNA-Gprc5a. Localized AAV delivery was adapted from a previous method [21]. In brief, anesthetized mice received palatal gingival injections adjacent to maxillary second molars using a 33-G Hamilton syringe (2 µL/site; 5 × 10¹¹ viral particles/µL). Transduction efficiency was confirmed by qRT-PCR after 14 days of injection. Periodontal tissues from mice were dissected under stereomicroscopic guidance. Following extraction of the second molars, periodontal tissues surrounding these teeth were separated and stored in RNAlater™ solution (Byotime). Periodontal tissues from the same experimental group were pooled to obtain sufficient RNA yield for qRT-PCR analysis, as individual samples produced suboptimal RNA quantities. Establishment of Murine Experimental Periodontitis All mice were initially anesthetized with pentobarbital sodium (40 mg/kg body weight, Sigma-Aldrich, USA). Following a 2-week injection of AAV, 5−0 silk ligature was gently tied around the maxillary second molar under inhalation anesthesia and maintained for 2 weeks. During the ligation period, LPS solution (E. coli 5000 µg/mL) was inoculated into the molar regions every other day for 2 weeks (total 6 times) [22]. Bilateral maxillae were harvested on day 14 following CO₂ euthanasia for further analysis. Histological Analysis Dissected tissues were fixed in 4% paraformaldehyde for 24 h at 4℃, followed by decalcification in 20% EDTA for 3–4 weeks. After dehydration, samples were paraffin-embedded and sectioned sagittally through the second molar’s long axis using a rotary microtome. Consecutive 5-µm sections were stained with hematoxylin and eosin (H&E) according to the manufacturer’s protocol (Solarbio, Beijing, China). Immunohistochemical (IHC) Staining The paraffin sections underwent trypsin-induced antigen retrieval after being deparaffinized and rehydrated. Then, the sections were incubated with primary antibodies against GPRC5A (1:500; Proteintech, Wuhan, China, 10309-1-AP), IL-6 (1:500; Abcam, Cambridge, UK, ab290735), IL-1β (1:500; Abcam, ab283818), TNF-α (1:500; Proteintech, 26405-1-AP), β-arrestin 2 (ARRB2) (1:500; Santa Cruz Biotechnology, Dallas, Texas, USA, sc-365445), and eukaryotic elongation factor 2 phosphorylation (p-EEF2) (1:500; CST, Danvers, MA, USA, 2331 S). Following secondary antibody incubation, immunoreactivity was visualized using 3,3′-diaminobenzidine (DAB; Zhongshanjinqiao, Beijing, China). Quantitative analysis focused on the periodontal ligament within the sub-furcation region of second molars. Positive expression was quantified as average optical density (AOD), which was calculated as integrated optical density divided by the area of ROI. Microcomputed Tomography (µCT) Analysis The mice maxillae were harvested and then fixed in 4% paraformaldehyde at ambient temperature. Specimens were scanned using a high-resolution µCT system (SkyScan, Bruker, Billerica, MA) with acquisition parameters set at 70 kV, 100 µA, 5 μm isotropic voxel resolution, and 400 ms integration time per projection. Alveolar bone loss quantification was performed by measuring the cemento-enamel junction (CEJ) to alveolar bone crest (ABC) distance at ligature-induced periodontitis sites of second molars. Bone microarchitecture parameters, including bone volume fraction (bone volume/total volume, BV/TV, %), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were analyzed in CTAn software. Periapical regions of interest (ROI) surrounding second molars were manually contoured on serial axial planes, extending from root furcation to apex while excluding root structures [23]. Periodontal Tissue Collection and PDLCs Culture The present study was in accordance with the Helsinki Declaration revised in 2013 and approved by the Medical Ethics Committee of Stomatological Hospital, Shandong University, Jinan, China (Permit Number: 20211112). A total of six participants were enrolled, comprising a healthy group (2 male/1 female) and a periodontitis group (1 male/2 female). Periodontal tissues from healthy individuals were obtained during impacted third molar extraction or crown lengthening surgery, while tissues from patients with periodontitis were collected during periodontal flap operations. All the three participants were classified as having Grade III periodontitis according to the current classification system [24], with inflamed periodontal tissues sampled from sites demonstrating pocket depths ≥ 6 mm. Patients with smoking history, diabetes, obesity, hypertension, or systemic infectious conditions were excluded. Additionally, individuals who had received antibiotics or anti-inflammatory medications within the past 3 months were not enrolled. Third molars were collected from 6 patients, aged 16 to 20 years, with no oral or systemic diseases. Under sterile conditions, periodontal ligament was gently scratched off the middle third of the root and digested in a solution of 3000 µg/mL type I collagenase and 4000 µg/mL Dispase II (Sigma-Aldrich) for 2 h at 37℃. After the centrifugation, the cell pellet was resuspended in α­-minimum essential medium (α­MEM, Hyclone, USA) with 20% foetal bovine serum (FBS, Procell Life Science and Technology, Wuhan, China) and 1% penicillin–streptomycin solution (Gibco, Carlsbad, CA, USA) and incubated at 37℃ in a 95% O2 and 5% CO2 humidified atmosphere. Cells from passages 3–5 were used for subsequent experiments. PDLCs Treatment with Small Interfering RNA (siRNA) Upon attaining 70% confluency, PDLCs were transfected with GPRC5A-siRNA (5′-CCUAGUCCAGGAUGUUAUTT-3′ and 5′-AUAACAUCCUGGACUAGGCTT-3′, siGPRC5A, GenePharma, Shanghai, China) or negative control (5′-UUCUCCGAACGUGUCACGUTT-3′ and 5′-ACGUGACACGUUCGGAGAATT-3′, siNC, GenePharma) using Lipofectamine® 2000 (Invitrogen, Waltham, MA, USA). The transfected cells were prepared for the following experiments. To investigate the inflammatory regulation mechanism of GPRC5A in vitro, PDLCs were stimulated with 1 µg/mL LPS at 2 h, 6 h, 12 h, and 24 h. Immunocytochemistry After siRNA transfection, PDLCs were stimulated with 1 µg/mL LPS for 1 h. Cells were fixed in precooled methanol for 15 min, permeabilized with 0.2% Triton X-100 (Solarbio) for 5 min, and blocked with 10% normal goat serum for 1 h. After overnight incubation at 4℃ with rabbit anti-NF-κB p65 primary antibody (1:500; Abcam, ab32536), samples underwent three PBS washes and were incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody (1:500; Proteintech, SA00013-1) in the dark for 1 h at 37℃. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole for 5 min (DAPI; Proteintech). Images were observed under a fluorescence microscope (OLYMPUS IX73, Tokyo, Japan) in the darkroom and captured by the camera and imaging software (OLYMPUS cellSens Standard 1.17). Co-immunoprecipitation (Co-IP) Assay To check whether ARRB2/EEF2 interaction occurs in vivo, PDLCs lysates were prepared using NP-40 lysis buffer (Byotime, Shanghai, China) supplemented with 1% PMSF. For Co-IP, 1000 µg total protein was incubated overnight at 4℃ with 5 µg anti-ARRB2 antibody (Santa Cruz Biotechnology) or IgG control (Santa Cruz Biotechnology). Immune complexes were captured with Protein A/G agarose beads (Santa Cruz Biotechnology) for 4 h at 4℃. The beads were collected by centrifugation at 12,000 g, followed by 3 washes and western blot analysis. Statistical Analysis Data are presented as mean±standard deviation (SD). Statistical analyses were conducted using Student t-test for two groups and one-way analysis of variance (ANOVA) for multiple groups by using GraphPad Prism 9 (GraphPad, San Diego, CA). For ANOVA results reaching significance (P < 0.05), post hoc testing was conducted using Dunnett’s or Tukey’s tests as appropriate. All experiments included three independent biological replicates. Statistical significance was defined at P < 0.05. Results GPRC5A Expression was Upregulated in Inflamed Periodontal Tissues To examine GPRC5A expression dynamics in periodontal tissues under physiological and inflammatory conditions, we collected periodontal specimens from periodontally healthy donors and periodontitis patients, respectively. The IHC analysis revealed weak GPRC5A immunoreactivity in connective tissues of healthy controls. In inflamed periodontal tissues, however, exhibited increased inflammatory cells and stronger positive GPRC5A expression in connective tissues (Fig. 1a, b, P < 0.001). In a small exploratory cohort (n = 3 per group), we observed a trend of increased GPRC5A expression in periodontitis tissues compared to healthy controls. However, due to the very small sample size, these findings should be considered preliminary and exploratory, and require validation in larger independent cohorts. Then, we established a murine periodontitis model simulating the human periodontitis progression. To further investigate the role of GPRC5A in experimental murine periodontitis, AAV-NC or AAV-shRNA-Gprc5a was transfected into mice, followed by ligation of the maxillary second molars with 5-0-silk sutures and local administration of LPS (Fig. 1c). On 14 days, the gingiva and bone tissues around the second molars of mice were harvested. qRT-PCR and IHC confirmed that GPRC5A was upregulated in periodontitis groups versus controls (Fig. 1d-f, P < 0.001). Furthermore, GPRC5A expression was successfully downregulated by AAV-shRNA-Gprc5a in both control and periodontitis settings compared to their respective AAV-NC groups, confirming effective viral transduction (Fig. 1d-f, P < 0.001). Fig. 1GPRC5A expression was upregulated in inflamed periodontal tissues (a) H&E staining for periodontal tissues from healthy controls and periodontitis patients. (b) IHC staining and corresponding integrated optical density per area (n = 5) for GPRC5A in periodontal tissues from healthy controls and periodontitis patients. (c) Schematic illustration of AAV injection and establishment of mice periodontitis (created with BioRender.com). (d) GPRC5A mRNA levels in periodontal tissues surrounding maxillary second molars from Control mice and Periodontitis mice (n = 3) were quantified by qRT-PCR. (e) Representative IHC staining of GPRC5A in periodontal tissues from four groups. (f) Quantitative analysis of GPRC5A immunoreactivity (integrated optical density/area) in murine periodontal tissues (n = 5). Values were presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test) GPRC5A expression was upregulated in inflamed periodontal tissues (a) H&E staining for periodontal tissues from healthy controls and periodontitis patients. (b) IHC staining and corresponding integrated optical density per area (n = 5) for GPRC5A in periodontal tissues from healthy controls and periodontitis patients. (c) Schematic illustration of AAV injection and establishment of mice periodontitis (created with BioRender.com). (d) GPRC5A mRNA levels in periodontal tissues surrounding maxillary second molars from Control mice and Periodontitis mice (n = 3) were quantified by qRT-PCR. (e) Representative IHC staining of GPRC5A in periodontal tissues from four groups. (f) Quantitative analysis of GPRC5A immunoreactivity (integrated optical density/area) in murine periodontal tissues (n = 5). Values were presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test) GPRC5A Downregulation Alleviated Periodontal Inflammation in Mice After 14 days of ligation, µCT reconstruction revealed that the AAV-NC-Periodontitis group exhibited significant alveolar bone height reduction compared to the AAV-NC-Control group (Fig. 2a). Under periodontitis condition, AAV-NC mice demonstrated more severe alveolar bone resorption compared to AAV-shRNA-Gprc5a mice, with significantly reduced BV/TV%, Tb.N, and Tb.Th (Fig. 2b, P < 0.05). Both µCT and H&E staining analyses demonstrated a significantly greater CEJ-ABC distance in AAV-NC-Periodontitis mice compared to AAV-shRNA-Gprc5a-Periodontitis mice (Fig. 2b-d, P < 0.001). To further assess inflammatory status, inflammatory cytokines expression levels were evaluated. IHC staining revealed stronger IL-1β, IL-6, and TNF-α expression in the periodontal tissues of AAV-NC-Periodontitis mice compared with AAV-shRNA-Gprc5a-Periodontitis mice (Fig. 3a-f, P < 0.001). Periodontal tissues around the second molar were harvested to detect the mRNA level changes of proinflammatory cytokines. Consistent with the results of IHC staining, AAV-NC-Periodontitis mice exhibited significantly higher mRNA levels of Il-1β, Il-6, and Tnf-α than AAV-shRNA-Gprc5a-Periodontitis mice (Fig. 3g-i, P < 0.001). Collectively, these findings demonstrated that GPRC5A knockdown attenuated periodontitis progression in murine models through suppression of inflammatory responses. Fig. 2GPRC5A downregulation alleviated periodontal inflammation in mice (a) Micro-CT reconstructions (sagittal plane) of maxillae from above the four groups. (b) Bone morphometric parameters (CEJ-ABC distance, BV/TV%, Tb.N, Tb.Th) analyzed using CTAn software (n = 6). (c) H&E-stained sections demonstrated alveolar bone height changes in above four groups (red dashed lines: CEJ and ABC levels). (d) CEJ-ABC distances were quantified from histomorphometric analysis (n = 6). Values were presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test). Al, alveolar bone; de, dentin GPRC5A downregulation alleviated periodontal inflammation in mice (a) Micro-CT reconstructions (sagittal plane) of maxillae from above the four groups. (b) Bone morphometric parameters (CEJ-ABC distance, BV/TV%, Tb.N, Tb.Th) analyzed using CTAn software (n = 6). (c) H&E-stained sections demonstrated alveolar bone height changes in above four groups (red dashed lines: CEJ and ABC levels). (d) CEJ-ABC distances were quantified from histomorphometric analysis (n = 6). Values were presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test). Al, alveolar bone; de, dentin Fig. 3GPRC5A knockdown inhibited inflammatory reactions in periodontitis (a) through (c) IHC staining for IL-1β, IL-6, and TNF-α in periodontal tissues from AAV-NC-Control mice, AAV-shRNA-Gprc5a-Control mice, AAV-NC-Periodontitis mice and AAV-shRNA-Gprc5a-Periodontitis mice. (d) through (f) Integrated optical density per area for IL-1β, IL-6, and TNF-α. (g) through (i) The mRNA levels of Il-1β, Il-6, and Tnf-α in periodontal tissues from the above four groups. Values were presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test) GPRC5A knockdown inhibited inflammatory reactions in periodontitis (a) through (c) IHC staining for IL-1β, IL-6, and TNF-α in periodontal tissues from AAV-NC-Control mice, AAV-shRNA-Gprc5a-Control mice, AAV-NC-Periodontitis mice and AAV-shRNA-Gprc5a-Periodontitis mice. (d) through (f) Integrated optical density per area for IL-1β, IL-6, and TNF-α. (g) through (i) The mRNA levels of Il-1β, Il-6, and Tnf-α in periodontal tissues from the above four groups. Values were presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test) Downregulation of GPRC5A Suppressed the LPS-induced Expression of Pro-inflammatory Cytokine Genes and the Activation of the NF-κB Signaling Pathway in PDLCs To further investigate the expression level of GPRC5A in vitro, PDLCs were cultured and stimulated with LPS (Fig. 4a) at different time points. The expression of GPRC5A was elevated at all time points (Fig. 4b, P < 0.01) and reached its peak after 6 h of stimulation. To explore the effect of GPRC5A in periodontitis pathogenesis, GPRC5A was knocked down through siGPRC5A transfection. The results of western blot and qRT-PCR both confirmed that GPRC5A was successfully downregulated (Fig. 4c-e, P < 0.05). To further explore the regulation mechanism of GPRC5A in vitro, PDLCs were transfected with siGPRC5A and then stimulated with LPS for 6 h. qRT-PCR was employed to determine the effect of GPRC5A downregulation on LPS‐induced inflammatory response. The results showed that LPS significantly augmented the expression of IL‐8, IL‐1β, IL‐6, and PTGS2 at gene level, while downregulation of GPRC5A inhibited the upregulated inflammatory cytokine expression for LPS challenge (Fig. 4f, P < 0.05). To clarify the mechanism of the inhibitory effect of downregulation of GPRC5A, we detected the activation of NF‐κB, a signaling pathway which is responsible for LPS‐induced inflammatory cytokine production. The activation of NF‐κB was determined with the phosphorylation of p65 and IκBα and subsequent translocation of NF‐κB p65 from the cytoplasm to the nucleus [25]. Western blot analysis demonstrated significant LPS-induced upregulation of phospho‐IκBα (p‐IκBα) and phospho‐NF‐κB p65 (p‐p65), which was attenuated by GPRC5A knockdown relative to the LPS group (Fig. 4g, h, P < 0.05). As shown in Fig. 4i and j, nuclear translocation of NF‐κB p65 was examined employing immunofluorescence staining. NF‐κB p65 of untreated cells was predominantly localized in the cytoplasm and partly translocated to the nucleus when stimulated with LPS. However, when knocked down the expression of GPRC5A, LPS‐induced nuclear translocation was blocked (***P < 0.001). GPRC5A knockdown significantly reduced LPS‑induced mRNA levels of the classical NF-κB target genes IL-6, IL-1β, IL-8, and PTGS2, consistent with the observed changes in p-p65 and p65 nuclear translocation. Fig. 4Downregulation of GPRC5A suppressed the LPS-induced expression of pro-inflammatory cytokine genes and the activation of the NF-κB signaling pathway in PDLCs (a) Schematic illustration of the siRNA transfection (created with BioRender.com). (b) PDLCs were stimulated with 1 µg/mL LPS for 2, 6, 12, and 24 h. The mRNA expression levels of GPRC5A were determined by qRT-PCR (one-way ANOVA and Dunnett test). ***P < 0.001 versus NC group at all time points (2, 6, 12, 24 h). (c) PDLCs were transfected with siRNA and total RNA was extracted after 24 and 48 h. The relative mRNA expression of GPRC5A were normalized to negative control (NC) group (Student t-test). ***P < 0.001 versus NC group. (d) and (e) PDLCs were transfected with siRNA and treated with or without LPS. GPRC5A expression in PDLCs was quantified by western blot and qRT-PCR analysis (one-way ANOVA and Tukey test). (f) The mRNA expression levels of IL-8, IL-1β, IL-6 and PTGS2 were evaluated by qRT-PCR (one-way ANOVA and Tukey test). (g) and (h) After GPRC5A was downregulated in PDLCs, NF-κB signaling pathways were examined by western blot analysis with or without LPS treatment and corresponding quantitative analyses of expression of p-p65 relative to p65, and p-IκBα relative to IκBα (one-way ANOVA and Tukey test). (i) The nuclear translocation of NF-κB p65 was evaluated by immunofluorescence staining (NF‐κB p65, green fluorescent signals; DAPI, blue fluorescent signals). (j) Quantitative analyses of nucleus and cytoplasm distribution of NF‐κB p65. Values were presented as mean±SD. *P < 0.05, **P < 0.01, ***P < 0.001 Downregulation of GPRC5A suppressed the LPS-induced expression of pro-inflammatory cytokine genes and the activation of the NF-κB signaling pathway in PDLCs (a) Schematic illustration of the siRNA transfection (created with BioRender.com). (b) PDLCs were stimulated with 1 µg/mL LPS for 2, 6, 12, and 24 h. The mRNA expression levels of GPRC5A were determined by qRT-PCR (one-way ANOVA and Dunnett test). ***P < 0.001 versus NC group at all time points (2, 6, 12, 24 h). (c) PDLCs were transfected with siRNA and total RNA was extracted after 24 and 48 h. The relative mRNA expression of GPRC5A were normalized to negative control (NC) group (Student t-test). ***P < 0.001 versus NC group. (d) and (e) PDLCs were transfected with siRNA and treated with or without LPS. GPRC5A expression in PDLCs was quantified by western blot and qRT-PCR analysis (one-way ANOVA and Tukey test). (f) The mRNA expression levels of IL-8, IL-1β, IL-6 and PTGS2 were evaluated by qRT-PCR (one-way ANOVA and Tukey test). (g) and (h) After GPRC5A was downregulated in PDLCs, NF-κB signaling pathways were examined by western blot analysis with or without LPS treatment and corresponding quantitative analyses of expression of p-p65 relative to p65, and p-IκBα relative to IκBα (one-way ANOVA and Tukey test). (i) The nuclear translocation of NF-κB p65 was evaluated by immunofluorescence staining (NF‐κB p65, green fluorescent signals; DAPI, blue fluorescent signals). (j) Quantitative analyses of nucleus and cytoplasm distribution of NF‐κB p65. Values were presented as mean±SD. *P < 0.05, **P < 0.01, ***P < 0.001 GPRC5A Regulated Inflammation through ARRB2-EEF2 Interaction-Mediated Modulation of EEF2 Phosphorylation The above experimental findings have demonstrated that GPRC5A downregulation significantly attenuated LPS-induced inflammatory responses and NF-κB pathway activation in PDLCs. However, the molecular mechanisms of downstream GPRC5A remain unclear. As GPCRs are capable of transmitting downstream signaling through the mediation of G protein heterotrimers and arrestin proteins, a systematic screening of key signaling mediators downstream of GPRC5A was performed. qRT-PCR analysis showed no significant changes in G protein subunits or β-arrestin1 (ARRB1) mRNA expression upon GPRC5A downregulation and LPS stimulation (Supplementary Figure S1). Conversely, both western blot and qRT-PCR results demonstrated significant upregulation of ARRB2 at protein and mRNA levels following LPS stimulation (Fig. 5a-c, P < 0.05). This upregulation was attenuated upon GPRC5A knockdown, suggesting ARRB2 may play a regulatory role in GPRC5A-mediated inflammatory processes. Therefore, ARRB2 was selected for further mechanistic investigation. ARRB2-interacting proteins were identified through immunoprecipitation (IP) followed by shotgun proteomics analysis. Venn diagram analysis revealed 23 overlapping proteins between LPS and siGPRC5A + LPS groups, which were predominantly associated with oxidative stress, protein synthesis, immune response, and inflammatory pathways (Fig. 5d; Supplementary Table S2). Candidate proteins were further screened through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. GO and KEGG analyses revealed that the AMP-activated protein kinase (AMPK) signaling pathway was significantly enriched in both the LPS group and siGPRC5A + LPS group when compared to the NC group (Fig. 5e; Supplementary Figure S2). Subsequently, proteins associated with this pathway were systematically screened. Among these candidates, EEF2 was identified with four unique peptide counts, demonstrating higher confidence in identification (Supplementary Table S3). Co-IP and western blot confirmed ARRB2-EEF2 interaction. LPS stimulation increased ARRB2 levels and EEF2 phosphorylation, while GPRC5A knockdown attenuated both effects (Fig. 5f, P < 0.05). In vivo results showed the same tendency. As shown in the IHC staining images (Fig. 5g), stronger immunoreactivity of EEF2 phosphorylation (p-EEF2) was detected in the AAV-NC-Periodontitis mice compared with the AAV-shRNA-Gprc5a-Periodontitis mice (P < 0.001). The expression differences of p-EEF2 between AAV-NC-Control and AAV-shRNA-Gprc5a-Control mice were not significant (Fig. 5g). Furthermore, we examined the expression of ARRB2, which demonstrated a significantly higher level of ARRB2 in AAV-NC-Periodontitis mice compared to AAV-NC-Control mice (Fig. 5h, P < 0.001). Conversely, GPRC5A downregulation was found to suppress ARRB2 overexpression under periodontal inflammatory condition (Fig. 5h, P < 0.001). Overall, these findings, consistent with the in vitro results, suggested that the downregulation of GPRC5A exerted a significant preventive effect against periodontitis progression, which might be related to the suppression of EEF2 phosphorylation in mice (Fig. 6). Fig. 5GPRC5A regulated inflammation through ARRB2-EEF2 interaction-mediated modulation of EEF2 phosphorylation. (a) through (c) PDLCs were transfected with siNC or siGPRC5A and treated with or without LPS, the expression levels of ARRB2 were evaluated by (a, b) western blot and (c) qRT-PCR (one-way ANOVA and Tukey test). (d) VENN diagram. VENN diagram was performed by the analysis platform (Shanghai Genechem Co., Ltd.). (e) KEGG pathway enrichment analysis of genes of LPS group and siGPRC5A + LPS group. (f) Co-IP and western blot analysis showed the interaction between ARRB2 and EEF2, and the protein levels of p-EEF2 (one-way ANOVA and Tukey test). (g) and (h) IHC staining and integrated optical density per area for p-EEF2 and ARRB2 in periodontal tissues from AAV-NC-Control mice, AAV-shRNA-Gprc5a-Control mice, AAV-NC-Periodontitis mice and AAV-shRNA-Gprc5a-Periodontitis mice. Values are presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test) GPRC5A regulated inflammation through ARRB2-EEF2 interaction-mediated modulation of EEF2 phosphorylation. (a) through (c) PDLCs were transfected with siNC or siGPRC5A and treated with or without LPS, the expression levels of ARRB2 were evaluated by (a, b) western blot and (c) qRT-PCR (one-way ANOVA and Tukey test). (d) VENN diagram. VENN diagram was performed by the analysis platform (Shanghai Genechem Co., Ltd.). (e) KEGG pathway enrichment analysis of genes of LPS group and siGPRC5A + LPS group. (f) Co-IP and western blot analysis showed the interaction between ARRB2 and EEF2, and the protein levels of p-EEF2 (one-way ANOVA and Tukey test). (g) and (h) IHC staining and integrated optical density per area for p-EEF2 and ARRB2 in periodontal tissues from AAV-NC-Control mice, AAV-shRNA-Gprc5a-Control mice, AAV-NC-Periodontitis mice and AAV-shRNA-Gprc5a-Periodontitis mice. Values are presented as mean±SD. The superscript letter a denoted statistically significant differences between AAV-NC-Periodontitis and AAV-NC-Control (P < 0.05); b denoted statistically significant differences between AAV-shRNA-Gprc5a-Periodontitis and AAV-shRNA-Gprc5a-Control (P < 0.05); ***P < 0.001 versus AAV-NC-Periodontitis mice (one-way ANOVA and Tukey test) Fig. 6Schematic illustration of the regulatory role and mechanism of GPRC5A in periodontal inflammation Schematic illustration of the regulatory role and mechanism of GPRC5A in periodontal inflammation Discussion Previous studies indicated that GPRC5A deficiency differentially modulates inflammation, exacerbating pulmonary responses while attenuating colonic inflammation, which may be tissue-specific and dependent on the stage of inflammatory progression [16–18, 26, 27]. However, its role in periodontitis had not previously been investigated. In this study, GPRC5A expression was detected at low levels in periodontal tissues, with significant upregulation observed in inflamed periodontal tissues. Although histomorphology examination suggests GPRC5A expression in PDLCs, epithelial cells, and infiltrating leukocytes, we have not performed double staining to definitively identify each cell type. Previous studies [16, 17] have shown GPRC5A expression in macrophages, where it regulates inflammatory responses, raising the possibility that immune cell derived GPRC5A contributes to periodontitis. Therefore, future studies employing double immunofluorescence with cell‑type‑specific markers, cell‑type‑specific knockout mice, or single‑cell RNA sequencing would help clarify the cellular sources and relative contributions of GPRC5A to periodontal inflammation. The human tissue analysis included only three healthy and three periodontitis samples, with an age mismatch (healthy: 18–25 years; periodontitis: 35–60 years). Consequently, these results should be considered preliminary, and further validation in adequately powered cohorts would be valuable to support their statistical and clinical relevance. To further investigate the role of GPRC5A in periodontitis, we established a murine model following local, AAV-mediated knockdown of GPRC5A via periodontal injection. AAV has been widely utilized in animal studies and gene therapy due to its non-pathogenicity, low immunogenicity, and stable transgene expression [28]. Therefore, local AAV injection was employed to achieve GPRC5A knockdown, with qRT-PCR and IHC staining performed to validate knockdown efficiency. The results demonstrated significantly reduced GPRC5A expression in periodontal tissues of AAV-shRNA-Gprc5a mice compared to AAV-NC mice, confirming successful AAV-mediated GPRC5A knockdown in periodontal tissues. To simulate the dynamic progression of periodontitis, an experimental periodontitis model was established through ligature placement around the maxillary second molars combined with local LPS injection. The combined ligature + LPS model may over-represent acute inflammatory components; therefore, our key findings should be validated in a ligature-only chronic model in the future. The effects of GPRC5A knockdown on periodontitis were assessed through µCT, H&E staining, and IHC analysis. µCT revealed significantly greater alveolar bone resorption around the maxillary second molars in Periodontitis groups compared to Control groups, confirming the successful establishment of the periodontitis model. Under periodontitis conditions, AAV-NC mice exhibited more severe alveolar bone destruction and attachment loss compared to AAV-shRNA-Gprc5a mice, with significantly lower BV/TV%, Tb.Th and Tb.N than AAV-shRNA-Gprc5a mice. H&E staining similarly demonstrated significantly reduced attachment loss in AAV-shRNA-Gprc5a mice compared to AAV-NC mice following periodontitis induction. To further evaluate the level of periodontal inflammation, mRNA was extracted from periodontal tissues surrounding the maxillary second molars, and qRT-PCR was performed to quantify inflammatory cytokine expression in periodontal tissues. The results demonstrated significantly lower expression of Il-1β, Il-6, and Tnf-α in periodontal tissues of AAV-shRNA-Gprc5a-Periodontitis mice compared to AAV-NC-Periodontitis mice, consistent with the IHC results, indicating that GPRC5A knockdown significantly attenuated periodontal inflammatory responses. The protective effect of GPRC5A knockdown on alveolar bone loss could be mediated by increased osteoblast activity, decreased osteoclastogenesis, or both. Because we did not evaluate osteogenic markers (Runt-related Transcripition Factor, Runx2, osteocalcin, osteopontin) or osteoclast activity (Translate-Resistant Acid Phosphatase, TRAP staining), the cellular mechanisms underlying bone preservation remain unclear. Future studies should also examine whether AAV mediated GPRC5A knockdown after disease onset can reverse or halt established periodontitis, which would better model clinical intervention. In brief, our experiments found that AAV-mediated GPRC5A knockdown in periodontal tissues alleviated periodontal inflammation and alveolar bone loss. In vitro studies demonstrated significant LPS-induced upregulation of GPRC5A in PDLCs, while GPRC5A knockdown significantly attenuated LPS-induced pro-inflammatory cytokine release and NF-κB pathway activation in PDLCs. To explore the molecular mechanisms underlying GPRC5A-mediated inflammatory regulation, key downstream signaling molecules in the GPRC5A pathway were investigated. GPCR signaling is primarily regulated through interactions with G proteins and arrestins [29]. Agonist binding induces conformational changes in GPCRs, leading to G protein activation [30, 31]. G proteins are heterotrimeric GTP-binding proteins composed of α, β, and γ subunits, with Gα bound to GDP in the inactive state [32]. Upon activation, Gα dissociates from Gβγ subunits, and GDP is replaced by GTP, generating second messengers that initiate cellular responses [32, 33]. Arrestins serve as critical regulators of multiple signaling pathways, mediating GPCRs desensitization and intracellular trafficking [34]. The Gα protein family comprises four subfamilies: Gαs, Gαi/o, Gq/11, and Gα12/13, while ARRB1 and ARRB2 represent the most widely expressed arrestins [34, 35]. Therefore, we focused on screening these effector molecules. qRT-PCR and western blot analysis revealed significant upregulation of ARRB2 mRNA and protein levels in PDLCs following LPS stimulation, which was attenuated by GPRC5A knockdown, suggesting ARRB2 may participate in GPRC5A signaling transduction and exert synergistic effects. ARRB2 is a well-characterized downstream mediator of GPCR signaling and has been implicated in the regulation of NF-κB and inflammation [34, 35]. Subsequently, ARRB2-interacting proteins were identified through IP coupled with mass spectrometry analysis to further investigate the molecular mechanisms of GPRC5A regulation in inflammation. GO and KEGG pathway enrichment analyses were performed based on mass spectrometry data. The results demonstrated significant enrichment of the AMPK signaling pathway in both LPS and siGPRC5A + LPS groups. AMPK serves as a crucial regulator of both energy metabolism and inflammatory signaling pathways [36, 37]. Previous studies have demonstrated that AMPK knockdown inhibited LPS-induced NF-κB pathway activation and IL-1β release, highlighting its critical role in LPS-mediated inflammation [37, 38]. Under conditions of inflammation, one key mechanism by which AMPK exerts its regulatory effects is through the control of protein synthesis [38]. Notably, AMPK is a well-established upstream activator of eukaryotic elongation factor 2 kinase (EEF2K). Activated AMPK can directly phosphorylate and activate EEF2K, which in turn specifically phosphorylates and inactivates EEF2, thereby suppressing protein translation elongation [39]. Therefore, screening of AMPK pathway-related proteins identified EEF2 as a key candidate. EEF2 facilitates GTP-dependent ribosome translocation and plays essential roles in protein synthesis regulation [40]. Research indicates that EEF2 serves as a favorable prognostic biomarker for dense connective tissue repair, where active EEF2 promotes healing through modulation of inflammatory and proliferative processes during tissue repair [41]. However, LPS stimulation increases EEF2 phosphorylation, reducing its activity and impairing tissue repair processes [41, 42]. In our study, the physical interaction between ARRB2 and EEF2 was confirmed through Co-IP and western blot analysis. LPS stimulation upregulated ARRB2 expression and increased EEF2 phosphorylation, while GPRC5A knockdown attenuated both effects. These findings suggested that GPRC5A may regulate LPS-induced inflammatory responses in PDLCs through ARRB2-EEF2 interaction-mediated modulation of EEF2 phosphorylation. However, the mechanistic evidence for the GPRC5A‑ARRB2‑EEF2 axis is primarily correlative. Although Co‑IP demonstrated physical interaction between ARRB2 and EEF2, and GPRC5A knockdown reduced both ARRB2 expression and EEF2 phosphorylation, we did not perform rescue experiments (e.g., ARRB2 overexpression in GPRC5A‑knockdown cells, EEF2 phosphorylation modulation) that would directly establish causality. Our results suggested that LPS stimulation activated NF-κB signaling and increased EEF2 phosphorylation in PDLCs, while GPRC5A knockdown significantly inhibited EEF2 phosphorylation. Subsequently, the mechanisms underlying GPRC5A-mediated inflammatory regulation were further verified in vivo. IHC analysis revealed significantly increased ARRB2 expression and EEF2 phosphorylation following periodontitis induction, which was attenuated by GPRC5A knockdown, thereby alleviating periodontal inflammation. Previous study [42–44] supports a mechanistic link between EEF2 phosphorylation and NF-κB signalling via regulation of IκBα translation. Specifically, EEF2 phosphorylation inhibits translation elongation, which preferentially reduces the synthesis of short-half-life proteins such as IκBα, the primary cytoplasmic inhibitor of NF-κB. Decreased IκBα synthesis allows NF-κB nuclear translocation and pro-inflammatory gene activation. Conversely, when EEF2 phosphorylation is reduced, IκBα synthesis is restored, suppressing NF-κB activity. This provides biological plausibility for our inference that GPRC5A-mediated changes in EEF2 phosphorylation may influence NF-κB-driven inflammation. Nevertheless, the relationship between EEF2 phosphorylation and NF‑κB activation also remains correlative; direct manipulation of EEF2K or EEF2 phosphorylation status is needed to confirm directionality. In summary, this study demonstrated upregulated GPRC5A expression in periodontal tissues under inflammatory conditions. GPRC5A knockdown significantly alleviated alveolar bone destruction and attachment loss in murine periodontitis models. In vitro, GPRC5A knockdown attenuated LPS-induced inflammatory responses in PDLCs, which might be related to ARRB2-EEF2 interaction-mediated modulation of EEF2 phosphorylation. Additionally, GPRC5A may participate in inflammatory regulation by modulating EEF2 phosphorylation, thereby affecting NF-κB signaling. Based on these findings, we propose a working model in which GPRC5A downregulation mitigates periodontitis through the ARRB2-EEF2 axis, although causality remains to be directly tested in future functional studies. Despite some limitations, these results suggested GPRC5A as a potential and promising therapeutic target for periodontitis by modulating both inflammatory responses and bone homeostasis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1